A RICH AND ACCESSIBLE SOURCE OF INFORMATION
Novigenix is pioneering the development of unique ImmunoTranscriptomics precision medicine solutions through application of next generation machine learning and artificial intelligence tools to gene expression profile of circulating immune cells and tumor biopsies. The LITOSeek™ platform hosts a proprietary database of curated patient clinical profiles and corresponding RNAseq NGS data, providing a broad view of the immuno-transcriptome in healthy individuals and well-defined cancer patient cohorts.
DATABASE OF IMMUNOTRANSCRIPTOME PROFILES
The LITOSeek™ data platform is built upon proprietary clinical studies, academic collaborations, and biopharma partner programs incorporating data from well-defined cancer patient populations and healthy individuals. Furthermore, Novigenix has developed and continually perfected an in-house search engine that interrogates public databases to query specific clinical questions, perform quality control on RNAseq data, and import relevant available data to address specific questions. This data aggregation combined with proprietary analytical pipelines drive novel insights into the host immune response to onset and evolution of cancer and its therapy.
NOVIGENIX NEXT GENERATION TECHNOLOGY: LITOseek™
Seek biomarkers from liquid-based immuno-transcriptomic profiling of immune cells
STANDARDIZED IMMUNOTRANSCRIPTOMIC NGS WORKLFOW
LITOSeek™ provides standardized gene expression profiles of healthy individuals and well-defined cancer patient populations with curated clinical profiles. RNA extracted from patient samples (stabilized PBMC, whole blood, or tumor biopsy) is sequenced using optimized RNA-Seq protocols with proprietary standards. Industrialized workflow integrating control pools and quality control algorithms allows normalization, harmonization, and visualization of gene clusters to generate intelligent insights into patient sub-populations.
ARTIFICIAL INTELLIGENCE and BIOMARKERS
.
The LITOSeek™ data engine combines metadata from proprietary patient cohorts to provide accurate, AI-based predictive algorithms, based on genome-wide transcriptome profiling of patients. Novigenix Bioinformatics and Computational Biology expertise simplifies and accelerates the time of biomarker discovery and assay development, and provides Biopharma and Life Sciences Research customers an end-to-end solution.
